Related Terms

• Edetic acid, ethylene diamine tetraacetic acid (EDTA) therapy.

• Note: The term "chelation" may be used in general to refer to the use of any chemical in the blood to remove specific contaminants or toxins (for example, deferoxamine is used as a chelating agent to treat high levels of iron in the body). This type of chelation should not be confused with the use of EDTA therapy.

Background

• EDTA chelation became well known during the 1950s when it was proposed as a method to cleanse the blood and blood vessel walls of toxins and minerals. The technique involves infusing a chemical called ethylene diamine tetraacetic acid (EDTA) into the blood. The therapy is sometimes given by mouth and occasionally, other chemicals may be used.

• Initially, chelation was used to treat heavy metal poisoning. Some observers felt that other benefits occurred in patients receiving this therapy. Currently, chelation practitioners may recommended this treatment for diabetes, for clogged arteries in the heart or legs (called peripheral vascular disease), and for many other conditions. Twenty or more sessions may be recommended and can cost several thousand dollars.

Theory

• It has been proposed that treatment with chelation may break down cholesterol plaques in the arteries. Other mechanisms, such as the removal of calcium from these plaques and antioxidant properties, have also been suggested. However, there is little scientific evidence to support these theories.

• 500-1,000mL of a solution containing 50mg of disodium EDTA per kilogram of body weight is commonly injected into the vein. However, there is no standardized dosage. A single infusion may be used, or multiple infusions may be used daily, over several days or over several weeks.

• The American College for the Advancement of Medicine (ACAM) recommends adding heparin, magnesium chloride, a local anesthetic, several B-vitamins, and 4-20g of vitamin C to the chelation solution. This solution is infused slowly over 3.5-4 hours, one to three times a week. The ACAM recommends about 30 treatments for heart disease.

• Lifestyle modification, including, stress reduction, caffeine avoidance, alcohol limitation, quitting smoking, exercise and nutritional counseling, is encouraged.

• Chelation therapy is rarely administered through the mouth.

Scientific Evidence

Tradition/Theory

The below uses are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious and should be evaluated by a qualified health care professional.

• Alzheimer's disease, anemia, arthritis, autism, blood disorders, blood pressure, cataracts, chronic obstructive pulmonary disease (COPD), degenerative diseases (chronic), dementia, diabetes, digoxin toxicity, disease diagnosis, emphysema, encephalopathy, gallstones, gout, heart rhythm abnormalities, hemochromatosis, keratitis (inflammation of the cornea of the eye), macular degeneration, memory loss, neurodegenerative disorders, neuroprotection (oxaliplatin-related toxicity), osteoarthritis, osteoporosis, Parkinson's disease, rheumatoid arthritis, scleroderma, sexual development, sickle-cell disease, snakebites, stroke, systemic lupus erythematosus, vision problems, Wilson's disease.

Safety

Many complementary techniques are practiced by healthcare professionals with formal training, in accordance with the standards of national organizations. However, this is not universally the case, and adverse effects are possible. Due to limited research, in some cases only limited safety information is available.

• Chelation therapy may cause serious side effects, such as dangerously low calcium levels in the blood, bone marrow damage that leads to low levels of blood cells, kidney damage (with elevated creatinine levels), very low blood pressure, fast heart rate, increased risk of bleeding or blood clots (including interference with the effects of the blood thinning drug warfarin [Coumadin®]), bacterial blood infections, seizures, allergic or immune system reactions, heart rhythm abnormalities, and unstable blood sugar levels. Other side effects may include fever, nausea, vomiting, gastrointestinal upset, excessive thirst, increased sweating, headache, decreased thyroid function, fatigue, low white blood cell count (leukopenia), low blood platelet count (thrombocytopenia), or inflammation of the uvea (uveitis). Severe reactions have occurred causing people to stop breathing. Although deaths have been reported in people receiving chelation, it is unclear if chelation therapy was the direct cause. One possible cause may be due to the loss of calcium.

• Chelation may be dangerous in people with heart, kidney, or liver disease or with conditions affecting blood cells or the immune system. Use during pregnancy, breastfeeding, or in children may also be dangerous due to potential toxic effects.

Author Information

• This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).

References

Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.

1. Anand A, Evans MF. Does chelation therapy work for ischemic heart disease? Can Fam Physician 2003;49:307-309. View Abstract

2. Anderson TJ, Hubacek J, Wyse, DG, et al. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. J Am Coll Cardiol 2-5-2003;41(3):420-425. View Abstract

3. Bell SA. Chelation therapy for patients with ischemic heart disease. JAMA 4-24-2002;287(16):2077-2078. View Abstract

4. Chappell LT, Stahl JP, Evans R. EDTA chelation therapy for vascular disease: a meta-analysis using unpublished data. J Adv Med 1994;7:131-142.

5. Ernst E. Chelation therapy for coronary heart disease: an overview of all clinical investigations. Am Heart J 2000;140(1):139-141. View Abstract

6. Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy 2002;22(8):1067-1069. View Abstract

7. Huynh-Do U. [Gout nephropathy--ghost or reality?]. Ther Umsch 2004;61(9):567-569. View Abstract

8. Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA 1-23-2002;287(4):481-486. View Abstract

9. Morgan BW, Kori S, Thomas JD. Adverse effects in 5 patients receiving EDTA at an outpatient chelation clinic. Vet Hum Toxicol 2002;44(5):274-276. View Abstract

10. Najjar DM, Cohen EJ, Rapuano CJ, et al. EDTA chelation for calcific band keratopathy: results and long-term follow-up. Am J Ophthalmol 2004;137(6):1056-1064. View Abstract

11. Quan H, Ghali WA, Verhoef MJ, et al. Use of chelation therapy after coronary angiography. Am J Med 12-15-2001;111(9):686-691. View Abstract

12. Schnabel P, Erdmann E. [Is chelation therapy in coronary heart disease useful?]. Dtsch Med Wochenschr 8-16-2002;127(33):1715. View Abstract

13. Strassberg D. Chelation therapy for patients with ischemic heart disease. JAMA 4-24-2002;287(16):2077-2078. View Abstract

14. Villarruz MV, Dans AL, Tan FN. Chelation therapy for atherosclerotic cardiovascular disease [protocol]. Cochrane Database of Systematic Reviews 2002;(4):CD002785. View Abstract

15. Wong SS, Nahin RL. National Center for Complementary and Alternative Medicine perspectives for complementary and alternative medicine research in cardiovascular diseases. Cardiol Rev 2003;11(2):94-98. View Abstract